Genezen
PrivateLast Round
Series C
Jul 1, 2024
Total Funding Raised
$18.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Genezen operates in Healthcare & Life Sciences and is based in Indianapolis, Indiana. Its latest recorded funding round was a Series C round in July 2024.
Genezen is a biotechnology company that provides contract development and manufacturing services for viral vectors used in cell and gene therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Biotech Equipment, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genezen Comparables
Compare Genezen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VIVEbiotech | 90% | |
| ViroCell Biologics | 88% | |
| Andelyn Biosciences | 87% |
For institutional investors. Book with your work email.
Genezen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 1, 2024 | ||||
| Growth Equity | Nov 2, 2023 | ||||
| Growth Equity | Jan 5, 2021 |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 31% MoM.
- Nov 12, 2025
Partnered with Humane Genomics for oncolytic virus therapy.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 14, 2026
Genezen and Galibra Neuroscience announce a manufacturing partnership on Oct 14th '26 in Indiana to produce material for IND-enabling studies and manufacture clinical material for a planned Phase 1 trial of GAL005, an AAV-based gene therapy for SSADH deficiency.
- is_developingOct 5, 2026
Genezen announced a strategic manufacturing partnership with InterAct Therapeutics to advance clinical development of IAT-S2, an AAV8-based gene therapy targeting hepatocytes to modulate the liver microenvironment and suppress metastatic outgrowth in breast cancer liver metastases, in Indiana on Oct 5th '26.
- signs_new_clientOct 5, 2026
Genezen became InterActtx's selected manufacturing partner in Oct '26 after an evaluation citing its AAV development and manufacturing expertise, reliability and ability to support the program's critical timeline.
- has_revenueAug 10, 2026
Genezen reports $48M in revenue for 2024.
For institutional investors. Book with your work email.
Genezen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Genezen's valuation, stock price, and market status.
Is Genezen a public or private company?
Genezen is a private company.
What is the current stock price of Genezen?
Genezen is a private company, so its shares have no public market price. Caplight tracks Genezen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Genezen worth (valuation)?
Valuation information for Genezen is not publicly available.
Can I buy Genezen stock?
Genezen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Genezen's last funding round?
Genezen's most recent funding round was Series C on July 1, 2024.
Who are the main investors in Genezen?
Investor information for Genezen is not publicly disclosed.
Will Genezen IPO soon?
No public IPO plans have been announced for Genezen.
How can I track Genezen secondary market activity?
Caplight tracks bids, offers, and trades in Genezen's shares on secondary markets.